Document is current
Any future updates will be listed below
-
Authors
Norton, Samuel E.
Leman, Julia K. H.
Khong, Tiffany
Spencer, Andrew
Fazekas de St Groth, Barbara
McGuire, Helen M.
Kemp, Roslyn A. http://orcid.org/0000-0001-9092-1150
-
Funding
Funding for this research was provided by:
Cancer Research Trust (n/a)
Lottery Health Research (n/a)
Australasia Leukemia and Lymphoma Group (n/a)
NZSO Roche Translational Research Fellowship (n/a)
University of Otago (n/a)
Australian National Health and Medical Research Council Early Career Fellowship (GNT1037298)
International Society for the Advancement of Cytometry (ISAC) Marylou Ingram Scholars (n/a)
- License Information
-
More Information
Article History
Received: 6 November 2019
Accepted: 24 March 2020
First Online: 15 April 2020
Ethics approval and consent to participate
: For Cohorts 1, 2 and 3, the study was approved by the Health and Disability Ethics Committee (#14/NTA/33) and all patients gave written informed consent prior to inclusion in the study in accordance with the Treaty of Helsinki.For Cohort 4, peripheral blood (PB, 10 mL) from multiple myeloma (MM) patients was obtained following written informed consent as per the Alfred Hospital Human Ethics Committee-approved protocol. ALLG MM14, Universal Trial Number U1111–1126-2829 was approved by the Alfred Office of Ethics and Research Governance. (#546/12) Trial public title<i>: A prospective randomized Phase II study of single agent pomalidomide maintenance</i> versus <i>combination pomalidomide and low dose dexamethasone maintenance following induction with the combination of pomalidomide and low dose dexamethasone in patients with relapsed and refractory myeloma previously treated with lenalidomide.</i>
: Not applicable.
: The authors declare that they have no competing interests.
